| Literature DB >> 15954051 |
Herman Mun-Cheung Lau1, Edwin Wai-Chi Lee, Caroline Ngar-Chi Wong, Gabriel Yin-Fat Ng, Alice Yee-Men Jones, David Shu-Cheong Hui.
Abstract
OBJECTIVE: To investigate the impact of severe acute respiratory syndrome (SARS) on the physical fitness and health-related quality of life (HRQOL) among SARS survivors.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15954051 PMCID: PMC7094462 DOI: 10.1016/j.apmr.2004.09.025
Source DB: PubMed Journal: Arch Phys Med Rehabil ISSN: 0003-9993 Impact factor: 3.966
Demographic Data and Cardiorespiratory Fitness Profile of the 171 Patients
| Characteristics | Men (n=60) | Women (n=111) | All Patients (N=171) |
|---|---|---|---|
| Age (y) (range, 17–89y) | 38.72±14.21 | 36.63±11.72 | 37.36±12.65 |
| Days of hospitalization | 24.05±13.73 | 20.60±6.97 | 21.79±9.93 |
| Post-SARS duration (d) | 84.36±17.99 | 80.45±18.64 | 81.79±18.46 |
| Resting heart rate (beats/min) | 86.10±12.42 | 86.91±12.50 | 86.63±12.44 |
| Resting rate of perceived exertion (median) | 0.5 | 0.5 | 0.5 |
| Resting Spo2 (%) | 97.73±1.07 | 98.36±1.14 | 98.14±1.16 |
| Resting respiratory rate (breath/min) | 18.52±4.47 | 19.39±4.35 | 19.08±4.40 |
| Medication | |||
| No medication | 53.30 | 51.40 | 52 |
| Steroid | 45.00 | 45.90 | 45.6 |
| Others | 1.70 | 2.70 | 2.4 |
| 6-minute walk distance | |||
| Distance covered (m) | 624.32±119.03 (n=60) | 583.66±94.34 (n=111) | 597.92±105.14 (n=171) |
| Chester step test | |||
| Predicted V̇o2max (mL·kg−1·min−1) | 38.47±7.39 (n=43) | 36.19±7.42 (n=91) | 36.92±7.46 (n=134) |
| No. of patients completing 5 test levels (%) | 24 (40) | 46 (41) | 70 (41) |
NOTE. Values are mean ± SD unless otherwise stated.
Abbreviation: Spo2, oxygen saturation as measured by pulse oximetry.
Any steroids or medications taken in the postdischarge phase.
Fig 1Means and SDs of the 6MWT and the Chester step test of SARS patients with sex comparison. Abbreviation: NA, not applicable (for age groups <5 patients).
Comparison of 6-Minute Walk Distance Between SARS Patients and Normative Data
| Group | Age (y) | Patients | Mean ± SD | 95% CI | |
|---|---|---|---|---|---|
| 1 | <20 | SARS (n=1) | NA | NA | NA |
| 2 | 20–29 | SARS (n=56) | 644.37±86.10 | .005 | 621.31–667.43 |
| Normative | 698.00±76.00 | ||||
| 3 | 30–39 | SARS (n=51) | 623.53±91.22 | .001 | 597.87–649.19 |
| Normative | 698.00±76.00 | ||||
| 4 | 40–49 | SARS (n=35) | 563.90±84.17 | .001 | 534.99–592.82 |
| Normative | 635.00±57.00 | ||||
| 5 | 50–59 | SARS (n=21) | 517.88±91.62 | .001 | 476.18–559.59 |
| Normative | 635.00±57.00 | ||||
| 6 | >60 | SARS (n=7) | 430.29±130.07 | .004 | 309.99–550.58 |
| Normative | 512.00±79.00 |
NOTE. Normative data provided by Coordinating Committee for Physiotherapy, Hospital Authority.
Abbreviation: NA, not applicable (for age group <5 patients).
Statistically significant at P<.05 (independent t test).
Relation Between Dependent Variables and Days of Hospitalizion, Post-SARS Duration, and Total Dosage of Medication
| Variables | HR | 6MWT | V̇ | AD | GM | Curl-Up | Push-Up | SF-36 (physical) | SF-36 (mental) |
|---|---|---|---|---|---|---|---|---|---|
| Hospitalization days | .022 | .03 | NS | .006 | NS | NS | NS | .005 | NS |
| Post-SARS duration | NS | .009 | NS | .021 | .021 | NS | NS | .007 | NS |
| Total medication dosage | NS | NS | .007 | NS | NS | .014 | NS | NS | NS |
NOTE. Values are P and (standardized β coefficient).
Abbreviations: AD, anterior deltoid strength; GM, gluteus maximus strength; HR, heart rate; NS, not significant.
Statistically significant at P<.05 (stepwise linear regression).
Results of Musculoskeletal Profile of SARS Patients
| Outcomes | Men | Women |
|---|---|---|
| Anterior deltoid strength | 26.50±10.32 | 17.37±5.99 |
| Gluteus maximus strength | 33.98±15.43 | 24.24±11.84 |
| Handgrip strength | 69.25±18.81 | 45.04±12.89 |
| Curl-up (repetitions in 1min) | 16.41±12.58 | 13.74±11.49 |
| Push-up (maximum repetitions in 1 trial) | 10.59±8.86 | 8.71±6.46 |
NOTE. Values are mean ± SD.
Summation of both sides.
Fig 2Means and SDs of number of curl-ups (repetitions per minute) and push-ups (maximum repetitions per trial) stratified by sex and age group.
Comparison of HRQOL Outcomes Between SARS Patients and Subjects With Normal Health
| Scale/Sample | Mean ± SD | % Floor | % Ceiling | 95% CI | |
|---|---|---|---|---|---|
| PF | |||||
| Men (n=55) | 74.36±22.20 | 0.00 | 9.09 | <.001 | 68.35–80.37 |
| Normative | 94.02±10.88 | ND | |||
| Women (n=108) | 67.08±20.98 | 0.00 | 3.70 | <.001 | 63.07–71.09 |
| Normative | 89.82±14.19 | ND | |||
| Total (n=163) | 69.54±21.61 | 0.00 | 5.52 | <.001 | 66.23–72.85 |
| Normative | 91.83±12.89 | 91.32–92.35 | |||
| RP | |||||
| Men (n=55) | 37.27±41.63 | 47.27 | 23.64 | <.001 | 26.01–48.53 |
| Normative | 85.31±28.38 | ND | |||
| Women (n=108) | 29.40±38.95 | 57.41 | 14.81 | <.001 | 21.96–36.84 |
| Normative | 79.79±32.96 | ND | |||
| Total (n=163) | 32.06±39.92 | 53.99 | 17.79 | <.001 | 25.95–38.17 |
| Normative | 82.43±30.97 | 81.19–83.67 | |||
| RE | |||||
| Men (n=55) | 56.36±45.30 | 34.55 | 45.45 | .003 | 44.11–68.62 |
| Normative | 72.34±37.88 | ND | |||
| Women (n=108) | 43.21±41.08 | 37.96 | 26.85 | <.001 | 35.37–51.05 |
| Normative | 71.04±38.80 | ND | |||
| Total (n=163) | 47.65±42.87 | 36.81 | 33.13 | <.001 | 41.09–54.21 |
| Normative | 71.66±38.36 | 70.13–73.19 | |||
| BP | |||||
| Men (n=55) | 76.36±23.38 | 0.00 | 33.36 | <.001 | 70.04–82.69 |
| Normative | 87.07±18.98 | ND | |||
| Women (n=108) | 64.94±25.15 | 0.00 | 23.15 | <.001 | 60.14–69.74 |
| Normative | 81.14±23.91 | ND | |||
| Total (n=163) | 68.79±25.09 | 0.00 | 27.61 | <.001 | 64.95–72.63 |
| Normative | 83.98±21.89 | 83.11–84.85 | |||
| SF | |||||
| Men (n=55) | 68.41±23.31 | 0.00 | 18.18 | <.001 | 62.10–74.72 |
| Normative | 91.45±16.00 | ND | |||
| Women (n=108) | 59.14±23.90 | 0.00 | 12.96 | <.001 | 54.58–63.70 |
| Normative | 90.96±17.08 | ND | |||
| Total (n=163) | 62.27±24.04 | 0.00 | 14.72 | <.001 | 58.59–65.95 |
| Normative | 91.19±16.57 | 90.53–91.82 | |||
| GH | |||||
| Men (n=55) | 55.89±20.90 | 1.82 | 1.82 | .203 | 50.24–61.44 |
| Normative | 59.32±19.43 | ND | |||
| Women (n=108) | 48.00±20.99 | 0.00 | 0 | .016 | 43.99–52.01 |
| Normative | 52.92±20.38 | ND | |||
| Total (n=163) | 50.66±21.33 | 0.61 | 0.61 | .001 | 47.41–53.91 |
| Normative | 55.98±20.18 | 55.17–56.79 | |||
| MH | |||||
| Men (n=55) | 72.51±19.26 | 0.00 | 12.73 | .801 | 67.30–70.72 |
| Normative | 73.07±15.93 | ND | |||
| Women (n=108) | 64.11±17.97 | 0.00 | 2.77 | <.001 | 60.68–67.64 |
| Normative | 72.53±17.13 | ND | |||
| Total (n=163) | 66.95±18.78 | 0.00 | 6.13 | <.001 | 64.08–69.82 |
| Normative | 72.79±16.57 | 72.13–73.45 | |||
| VT | |||||
| Men (n=55) | 58.09±19.09 | 0.00 | 0 | .142 | 52.93–63.25 |
| Normative | 61.67±17.59 | ND | |||
| Women (n=108) | 45.74±17.43 | 0.93 | 0.93 | <.001 | 42.41–49.07 |
| Normative | 59.00±19.48 | ND | |||
| Total (n=163) | 49.91±18.88 | 0.61 | 0.61 | <.001 | 47.02–52.80 |
| Normative | 60.27±18.65 | 59.53–61.02 |
NOTE. Normative data refers to the study conducted by Lam et al.21 Values are mean ± SD unless otherwise noted.
Abbreviations: BP, bodily pain; GH, general health; MH, mental health; ND, no data; PF, physical functioning; RE, role-emotional; RP, role-physical; SF, social functioning; VT, vitality.
Proportion of subjects with the lowest possible score.
Proportion of subjects with the highest possible score.
Statistically significant at P<.05.